(PRESS RELEASE) ANAHEIM, CA – International Veterinary Sciences, a developer and manufacturer of pet care products that promote health and wellness, has appointed Arthur Bedrosian as CEO and partner. Bedrosian comes to IVS after running several successful businesses over the past 30 years.
Most recently, Bedrosian served as CEO of publicly traded Lannett Co., a generic pharmaceutical company where he led growth from $10 million in fiscal 2000 to $700 million by fiscal 2018. Complementing Lannett’s organic growth with several strategic acquisitions, he expanded the company’s global reach and helped secure over 50 U.S. Food and Drug Administration abbreviated approvals and one new drug approval during his tenure. His background includes supplying veterinary prescription drugs to the veterinary market.
In his new role as CEO of IVS, Bedrosian will focus on growing the IVS business both domestically and internationally. He will continue to build the OTC pet supplement brand and lead efforts to create a new line of veterinary pharmaceutical products while leveraging his extensive experience in manufacturing, licensing and FDA compliance. Several products are being developed with anticipated release dates in the third quarter of 2018.
“On behalf of myself and our management team, we are incredibly pleased and excited to have someone of Arthur’s experience and leadership ability at IVS,” said Ara Bohchalian, president and chairman of International Veterinary Sciences. “We know that Arthur will bring forth a wealth of opportunities to build upon the success and take IVS to the next level in product delivery systems, health and innovation.”
